Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros











Intervalo de año de publicación
2.
Artículo en Chino | MEDLINE | ID: mdl-26248410

RESUMEN

OBJECTIVE: We aim to investigate the sonodynamic effect induced by hydroxyl acetylated curcumin (HAC) on THP-1 macrophages. METHODS: THP-1 derived macrophages (1 x 10(5) per milliliter) were cultured with HAC at a concentration of 5 µg/mL for 4 h and then exposed to pulse ultrasound treatment (0.5 W/cm2) for 5 min. Six hours later, cell viability analysis was performed with CCK-8 assay, apoptosis and necrosis analysis were detected with Annexin V/PI staining by flow cytometery. RESULTS: The cell viability of THP-1 macrophage decreased significantly in the group treated with the combination of HAC and ultrasound (P < 0.01), and HAC-SDT induced both apoptosis and necrosis in THP-1 macrophages, the apoptotic rate was higher than the necrotic rate with appropriate conditions, the maximum apoptosis/necrosis ratio was detected in sonodynamic therapy (SDT) group (P < 0.01). CONCLUSION: hAC-SDT was effective to induce THP-1 macrophages apoptosis.


Asunto(s)
Apoptosis , Curcumina/farmacología , Macrófagos/citología , Necrosis , Línea Celular , Supervivencia Celular , Humanos , Macrófagos/efectos de los fármacos , Ultrasonido
3.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-318439

RESUMEN

According to the characteristics of the etiology and pathogenesis of child cerebral palsy, on the basis of "regulating the mind in treatment of all kinds of diseases" and "regulating the functions of five zang organs with back-shu points", Professor DONG Gui-rong applied the penetrating needling technique on the scalp points and acupuncture at back-shu points of five zang organs in the treatment of child cerebral palsy. The valuable clinical experiences have been summarized as "regulating the mind with scalp needling technique, benefiting the brain and opening the orifice", "regulating five zang organs with back-shu points" and "integration of acupuncture and rehabilitation, and function reconstruction". Two effective cases were introduced.


Asunto(s)
Preescolar , Humanos , Masculino , Puntos de Acupuntura , Terapia por Acupuntura , Parálisis Cerebral , Terapéutica , Resultado del Tratamiento
5.
Cell Biol Int ; 33(10): 1095-101, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19616639

RESUMEN

The mechanism of action of Hydrogen sulfide (H(2)S) as a novel endogenous gaseous messenger and potential cardioprotectant is not fully understood. We therefore investigated the prevention of cardiomyocyte apoptosis by exogenous H(2)S and the signaling pathways leading to cardioprotection. Using a simulated ischemia-reperfusion (I/Re) model with primary cultured rat neonatal cardiomyocytes, I/Re induced a rapid, time-dependent phosphorylation of c-Jun N-terminal kinase (JNK), with significant elevation at 0.25 h and a peak at 0.5h during reperfusion. NaHS (H(2)S donor) significantly inhibited the early phosphorylation of JNK, especially at 0.5h. Both NaHS and SP600125 (specific JNK inhibitor) decreased the number of apoptotic cells, lowered cytochrome C release and enhanced Bcl-2 expression. When NaHS application was delayed 1h after reperfusion, the inhibition of apoptosis by H(2)S was negated. In conclusion, this is novel evidence that early JNK inhibition during reperfusion is associated with H(2)S-mediated protection against cardiomyocyte apoptosis.


Asunto(s)
Apoptosis/efectos de los fármacos , Citoprotección , Sulfuro de Hidrógeno/farmacología , Proteínas Quinasas JNK Activadas por Mitógenos/antagonistas & inhibidores , Miocitos Cardíacos/efectos de los fármacos , Animales , Antracenos/farmacología , Apoptosis/fisiología , Células Cultivadas , Citocromos c/antagonistas & inhibidores , Citocromos c/metabolismo , Miocitos Cardíacos/enzimología , Fosforilación/efectos de los fármacos , Fosforilación/fisiología , Proteínas Proto-Oncogénicas c-bcl-2/efectos de los fármacos , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Ratas , Ratas Wistar , Proteína X Asociada a bcl-2/efectos de los fármacos , Proteína X Asociada a bcl-2/metabolismo
6.
Basic Clin Pharmacol Toxicol ; 104(2): 101-6, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19143751

RESUMEN

The aim of the study was to investigate the functional profile of dendritic cells in patients with coronary heart disease and the effects of pravastatin on this. Forty-eight patients with coronary heart disease were divided into three groups: 16 treated with pravastatin 10 mg/day, 16 treated with pravastatin 20 mg/day and 16 not treated with pravastatin. Dendritic cells from 48 patients with coronary heart disease (before and 4 weeks after the treatment) and 16 healthy individuals were derived from peripheral blood. CD86 of dendritic cells was assessed by flow cytometry. Immunostimulatory capacity of dendritic cells was measured by mixed lymphocyte reaction. The levels of cytokines in the medium of mixed lymphocyte reaction were analysed. Blood lipids and high-sensitivity C-reactive protein were measured. Compared to normal group, more CD86+ dendritic cells were expressed in coronary heart disease and greater immunostimulatory capacity of dendritic cells in coronary heart disease was demonstrated. T lymphocytes in coronary heart disease in mixed lymphocyte reaction secreted higher levels of pro-inflammation cytokines and lower levels of anti-inflammation cytokines. CD86 expression significantly correlated with C-reactive protein, but did not correlate with low-density lipoprotein cholesterol. Both dosages of pravastatin markedly inhibited the function of dendritic cells and lowered C-reactive protein, which is independent of plasma cholesterol lowering. The anti-inflammatory effect of pravastatin showed no obvious difference between the two dosage groups. In conclusion, dendritic cells were activated in coronary heart disease and dendritic cell-mediated immune mechanisms may be involved in the pathogenesis of coronary heart disease. Pravastatin can inhibit dendritic cell activation, which is independent of plasma cholesterol lowering. Pravastatin in different doses showed no apparent differences in the inhibition of dendritic cell functions.


Asunto(s)
Enfermedad Coronaria/tratamiento farmacológico , Células Dendríticas/efectos de los fármacos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Pravastatina/uso terapéutico , Adulto , Anciano , Antígeno B7-2/inmunología , LDL-Colesterol/sangre , Enfermedad Coronaria/sangre , Enfermedad Coronaria/inmunología , Citocinas/inmunología , Células Dendríticas/inmunología , Relación Dosis-Respuesta a Droga , Femenino , Citometría de Flujo , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Inmunidad Innata/efectos de los fármacos , Masculino , Persona de Mediana Edad , Pravastatina/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA